← FDA DRUG APPROVALS

FDA NDA · NDA020757

AVAPRO

irbesartan

Sponsor: SANOFI AVENTIS US

APPLICATION
NDA020757
TYPE
NDA
ORIGINAL APPROVAL
1997-09-30
LATEST ACTION
2026-07-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription, Discontinued

Products

AVAPRO · ReferencePrescription
IRBESARTAN 300MG · TABLET · ORAL
AVAPRO · ReferenceDiscontinued
IRBESARTAN 75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
AVAPRO · ReferencePrescription
IRBESARTAN 150MG · TABLET · ORAL

Approval history

2026-07-24Labeling · Supplement 81 · standardAP
2025-08-01Labeling · Supplement 80 · standardLabelAP
2021-09-10Labeling · Supplement 74 · standardLabelAP
2021-05-11Labeling · Supplement 75 · standardLabelAP
2020-12-15Labeling · Supplement 71 · standardLetterAP
2018-07-20Labeling · Supplement 69 · standardLetterAP
2016-02-05Labeling · Supplement 67 · standardLetterAP
2016-02-05Labeling · Supplement 59 · unknownLetterAP
2015-01-05Manufacturing (CMC) · Supplement 65 · standardAP
2014-05-28Labeling · Supplement 64 · standardLetterAP
2013-10-10Manufacturing (CMC) · Supplement 63 · standardAP
2013-02-28Manufacturing (CMC) · Supplement 61 · standardAP
2012-09-12Labeling · Supplement 60 · unknownLetterAP
2012-01-18Labeling · Supplement 58 · unknownLabelAP
2011-12-08Labeling · Supplement 56 · unknownLabelAP
2011-08-01Labeling · Supplement 55 · unknownLetterAP
2007-07-31Manufacturing (CMC) · Supplement 44LabelAP
2006-04-21Labeling · Supplement 38 · standardLabelAP
2006-03-16Labeling · Supplement 39 · standardReviewAP
2005-11-21Labeling · Supplement 37 · standardLetterAP
2004-10-29Supplement · Supplement 33 · standardReviewAP
2004-07-21Supplement · Supplement 32 · standardReviewAP
2004-05-20Supplement · Supplement 31 · standardReviewAP
2004-01-02Supplement · Supplement 30 · standardReviewAP
2003-10-09Supplement · Supplement 27 · standardReviewAP
2003-09-09Supplement · Supplement 28 · standardReviewAP
2003-05-21Supplement · Supplement 26 · standardReviewAP
2003-05-01Supplement · Supplement 24 · standardReviewAP
2003-03-21Supplement · Supplement 23 · standardOtherAP
2003-03-21Supplement · Supplement 25 · standardOtherAP
2002-09-17Efficacy · Supplement 21 · priorityReviewAP
2002-07-19Manufacturing (CMC) · Supplement 22 · standardReviewAP
2001-09-26Labeling · Supplement 11 · standardReviewAP
2001-06-07Manufacturing (CMC) · Supplement 20 · standardReviewAP
2001-05-26Efficacy · Supplement 14 · standardReviewAP
2001-03-06Manufacturing (CMC) · Supplement 19 · standardReviewAP
2001-02-02Manufacturing (CMC) · Supplement 18 · standardReviewAP
2000-09-20Labeling · Supplement 17 · standardReviewAP
2000-08-23Manufacturing (CMC) · Supplement 10 · standardAP
2000-08-01Manufacturing (CMC) · Supplement 13 · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →